The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

However, both tirapazamine and RB6145 were far superior ( Figure 3A ) and had a highly significant impact on local control with >75% of treated mice showing no evidence of primary tumour re-growth during the course of the experiment (log-rank P <0.001 for both agents).

also in 132,142 other papers

Concomitant with the reduction in vessel density, irradiated NLCQ-1-treated tumours exhibited an increase in hypoxic fraction compared with saline-treated controls (13±3 vs 9±1 in controls), but again this did not achieve significance ( P >0.05).

also in 1,397 other papers